Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12901475 | 1.00 | GPR119 (0.46) | GPR119USP2SMN1; SMN2HPGDMEN1 | |
| SCHEMBL12901443 | 1.00 | GPR119 (0.46) | GPR119USP2SMN1; SMN2HPGDMEN1 | |
| SCHEMBL12901469 | 0.95 | GPR119 (0.49) | GPR119USP2SMN1; SMN2IDO1 | |
| SCHEMBL12901444 | 0.91 | USP2 (0.40) | GPR119USP2SMN1; SMN2HPGDMEN1 | |
| SCHEMBL12901471 | 0.91 | USP2 (0.40) | GPR119USP2SMN1; SMN2HPGDMEN1 | |
| SCHEMBL12901470 | 0.91 | USP2 (0.40) | GPR119USP2SMN1; SMN2HPGDMEN1 | |
| SCHEMBL12901473 | 0.89 | GPR119 (0.45) | GPR119USP2SMN1; SMN2IDO1 | |
| SCHEMBL12901472 | 0.89 | GPR119 (0.45) | GPR119USP2SMN1; SMN2IDO1 | |
| SCHEMBL12901445 | 0.89 | GPR119 (0.45) | GPR119USP2SMN1; SMN2IDO1 | |
| SCHEMBL26289064 | 0.86 | GPR119 (0.47) | GPR119USP2SMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099738-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2015-04-09 | — | — | US | disclosed |
| US-20150099738-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2015-04-09 | — | — | US | disclosed |
| US-8765735-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765735-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110034437-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034437-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| WO-2010135360-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034437-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | GPR119 27/4885USP2 725/4885SMN1; SMN2 4142/4885 |
| US-20150099738-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | GPR119 27/4885USP2 725/4885SMN1; SMN2 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.